GlassScriptPhysician profile
Charles C Assell, III
NPI 1962574137
$6,663.92
in general payments reported to CMS, 2019-2025
11 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $359 · 2021: $590 · 2022: $2,030 · 2023: $749 · 2024: $619 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,184.24 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,895.28 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,635.39 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Abb Con-Cise Optical Group LLC | $421.09 | 2020-2025 | Contact Lens, Spectacle Lenses |
| Sight Sciences, INC. | $162.79 | 2020-2023 | Omni Surgical System |
| Glaukos Corporation | $115.23 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $104.52 | 2019-2020 | |
| Rxsight INC | $86.60 | 2021 | |
| Allergan, INC. | $22.09 | 2022 | |
| Bausch & Lomb Americas INC. | $21.06 | 2022 | |
| Carl Zeiss Meditec, INC. | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Assell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.